TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14609312
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (5 g of glycine, glutamine, and niacin, twice daily for 3 weeks)
Study: 14609312
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 3 weeks)
Study: 24741361
Drug: 4 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 days of normal daily activity after 21 days of bed rest
Study: 22512878
Drug: Intravenous glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glutamine (0.5 g/kg/die for 7 days)
Study: 22512878
Drug: Normal amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal amino acid solution (same quantity for 7 days)
Study: 6352654
Drug: Ceftazidime (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (0.5 g every 12 h)
Study: 30233812
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Study: 30233812
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Study: 24131447
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prior pruritus treatment)
Study: 22244829
Drug: High-risk group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk group (AFP < 100 ng/mL, PRETEXT IV, vascular invasion, extra-hepatic intra-abdominal disease, metastases)
Study: 22244829
Drug: High-risk group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk group (PRETEXT IV, multifocal tumour, age > 5 years, AFP > 1.2 × 10(6) ng/mL)
Study: 10432408
Drug: L-arginine (ARG)
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (ARG) supplementation (0.2 g/kg body wt/day) for six months
Study: 2331951
Drug: Antacid gel
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid gel (buffering capacity 70 meq/10 ml)
Study: 20570122
Drug: Genistein aglycone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein aglycone (54 mg/day)
Study: 28241420
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg) and vitamin D3 (800 IU) - placebo
Study: 23962782
Drug: Tele-accelerometry (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-accelerometry (monthly 6MWTs)
Study: 1602293
Drug: Ketoprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (100 mg suppository)
Study: 1602293
Drug: Ergotamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine (2 mg suppository)
Study: 17441414
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with carbamylated allergoid (SLIT)
Study: 7603217
Drug: K-Y gel
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-Y gel (placebo)
Study: 20584525
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (1,050 mg/d of eicosapentaenoic acid (EPA) and 150 mg/d of docosahexaenoic acid (DHA))
Study: 19861864
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two types of dates
Study: 16903603
Drug: Red-hot needle
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Red-hot needle therapy
Study: 8193487
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K1 (2 mg)
Study: 1444522
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin K1 (1 mg)
Study: 8193487
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of oral vs intramuscular vitamin K1
Study: 31099036
Drug: Placebo (simulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (simulated laser therapy)
Study: 21656308
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg IM) and Neostigmine (1 mg IM)
Study: 12765311
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of inhaled corticosteroids
Study: 10872704
Drug: Warfarin (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (therapeutic INR 2.8-4.2)
Study: 10872704
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg Aspirin daily combined with Warfarin (INR 2.0-2.5)
Study: 1317928
Drug: Oat products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat products (3 g or more of soluble fiber)
Study: 6469082
Drug: Pentagastrin infusion
Normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentagastrin infusion test with cimetidine (200 mg bolus after one hour)
Study: 30005329
Drug: Sucralose (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (200 mg)
Study: 27285466
Drug: Apremilast 50
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 50 mg, administered twice daily for 9 doses
Study: 27285466
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg, administered as a positive control
Study: 19042325
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) in 9 weekly group sessions
Study: 15277619
Drug: PCV (procarbazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV (procarbazine, 60 mg/m2 on days 8 to 21; CCNU, 110 mg/m2 on day 1; and vincristine, 1.4 mg/m2 on days 8 and 29)
Study: 15277619
Drug: Temozolomide (TMZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (TMZ; 150 to 200 mg/m2 for 5 days every 4 weeks)
Study: 2878131
Drug: Ileu‐ANP infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileu‐ANP infusion (5 micrograms/min for 4 h)
Study: 26774608
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg per day
Study: 25139724
Drug: Intrauterine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine administration of 5 cc of 2% lidocaine
Study: 22873367
Drug: Routine fertility
Normalized name: Tests for fertility disturbances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine fertility work-up with additional (SIS and) hysteroscopy with on-the-spot treatment of predefined intrauterine abnormalities
Study: 3305118
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) 120 mg daily
Study: 21209232
Drug: Sibutramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (15 mg oral dose)
Study: 19591674
Drug: Active PEMF-treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PEMF-treatment for 60 days, four hours daily
Study: 19591674
Drug: Sham-treatment for
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-treatment for 60 days, four hours daily
Study: 7199332
Drug: Midazolam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.2 mg/kg)
Study: 9262801
Drug: Meperidine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (2.0 mg/kg)/Promethazine (1.0 mg/kg)
Study: 8331703
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin and Sequential compression devices
Study: 3581737
Drug: Cefoperazone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone (1 g)
Study: 23043721
Drug: PRO+LEU (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO+LEU (20 g casein protein + 2.5 g crystalline leucine)
Study: 23043721
Drug: PRO (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO (20 g casein protein)
Study: 22156381
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) 4 mg i.v. every 6 months for 2 years
Study: 22156381
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/day) without ZOL
Study: 15950351
Drug: Olanzapine in
Normalized name: olanzapine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine in monotherapy (OGm)
Study: 9649102
Drug: Thermal uterine
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal uterine balloon therapy
Study: 7977519
Drug: Topical intravaginal
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intravaginal clindamycin (dosages not specified, administered twice daily for 5 days)
Study: 28320484
Drug: Twice-daily control
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily control nutritional drink enriched with standard micronutrients.
Study: 3823637
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg sublingually)
Study: 28892807
Drug: General Osteopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Osteopathic Treatment (GOT)
Study: 27730033
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg daily isotretinoin (Group A)
Study: 27730033
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg alternate days isotretinoin (Group B)
Study: 23853000
Drug: MenC-CRM glycoconjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenC-CRM glycoconjugate vaccine (CRM-group)
Study: 23853000
Drug: Bivalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group)
Study: 23853000
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional doses of MenC vaccine (control group)
Study: 15164106
Drug: 0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/day nonesterified, nonhydrogenated plant sterols in low-fat milk (C)
Study: 14971151
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy including adaptation to intermittent normobaric hypoxia and medicines
Study: 7588666
Drug: 6 microliters
Normalized name: MICROLITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 microliters 0.25% bupivacaine + 0.05 mg kg‐1 midazolam
Study: 2278060
Drug: Oral sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sulfadoxine-pyrimethamine
Study: 396652
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg/day, 25 mg in the morning and midday and 50 mg at bed time)
Study: 29203731
Drug: Mechanical thrombectomy
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical thrombectomy plus rescue therapy for ICAS
Study: 22274319
Drug: Brachytherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachytherapy with a total dose of 15Gy to point A followed by radical surgery (arm BT)
Study: 22274319
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy with cisplatin 50 mg/m plus 5‐fluorouracil 750 mg/m at a 2‐week interval for 2 courses followed by radical surgery (arm IVCT)
Study: 17690950
Drug: Taurine treatment
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine treatment (2 g taurine 3 times a day for three months)
Study: 6140441
Drug: Component vaccine
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Component vaccine containing purified haemagglutinins (HAs) of Bordetella pertussis
Study: 6140441
Drug: Conventional whole-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional whole-cell vaccine
Study: 29626849
Drug: Nalbuphine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine at the ED95 dose (0.128 mg/kg)
Study: 29626849
Drug: Sufentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil at an equivalent dose
Study: 20886801
Drug: Medicated thread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicated thread moxibustion of traditional Zhuang nationality medicine
Study: 11882622
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/d) for up to 5 weeks
Study: 11882622
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ACEi treatment), n=7
Study: 7581139
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron infusion for 7 days during Bu/CY administration
Study: 121048
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oestriol + 2 mg oestradiol
Study: 121048
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg oestriol succinate + 1 mg oestradiol
Study: 12648884
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol
Study: 12648884
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oestradiol
Study: 28966211
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose PCV13 followed by PPV23 after 16 weeks (bDMARD)
Study: 28966211
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose PCV13 followed by PPV23 after 24 weeks (bDMARD)
Study: 28966211
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose PCV13 followed by PPV23 after 16 weeks (bDMARD)
Study: 28966211
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose PCV13 followed by PPV23 after 16 weeks (csDMARD)
Study: 22119746
Drug: Olanzapine orally
Normalized name: Olanzapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine orally disintegrating tablet (ODT) - mean dosage 15.2 mg
Study: 22119746
Drug: Oral standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral standard tablet (OST) - mean dosage 15.7 mg
Study: 17584312
Drug: Prednisolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (2 mg/kg/day in three divided doses for 3 days)
Study: 15020038
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg ibuprofen for 14 days
Study: 8458362
Drug: Quinapril once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril once daily (o.d.)
Study: 8458362
Drug: Quinapril twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril twice daily (b.i.d.)
Study: 3535399
Drug: Carbenicillin 10
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin 10 g every 8 h plus Gentamicin 80 mg every 8 h
Study: 3535399
Drug: Latamoxef 2
Normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Latamoxef 2 g every 8 h
Study: 3535399
Drug: Carbenicillin 10
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin 10 g every 8 h plus Mecillinam 800 mg every 8 h
Study: 21212710
Drug: FEN bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEN bolus infusion + DES inhalation
Study: 11789241
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine alone for three months.
Study: 11789241
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and Western medicine (TCM‐WM) therapy.
Study: 11789241
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine alone.
Study: 14533656
Drug: Medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medicines
Study: 28994212
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alfa-2B (HDI)
Study: 28994212
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (BCT and HDI)
Study: 14616416
Drug: Voriconazole 200
Normalized name: voriconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 200 mg twice daily + Indinavir 800 mg three times daily (Study A)
Study: 14616416
Drug: Voriconazole 200
Normalized name: voriconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 200 mg twice daily + Indinavir 800 mg three times daily (Study B)
Study: 14616416
Drug: Voriconazole 200
Normalized name: voriconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 200 mg twice daily + Placebo (Study A)
Study: 14616416
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg three times daily + Voriconazole 200 mg (Study B)
Study: 23115322
Drug: Low-dose beta-blockers
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose beta-blockers
Study: 30842172
Drug: Repeated-dose RSB
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated-dose RSB analgesia
Study: 30842172
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion RSB analgesia
Study: 21856006
Drug: Fluoroquinolone antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolone antibiotics (gatifloxacin 0.3%, moxifloxacin 0.5%, ofloxacin 0.3%)
Study: 15334790
Drug: Repaglinide plus
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide plus acarbose (2 mg repaglinide 15 min before breakfast followed by 100 mg acarbose with breakfast)
Study: 15334790
Drug: Repaglinide alone
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide alone (2 mg)
Study: 11524040
Drug: 400 i.u.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 i.u. of oral alpha-tocopherol daily for 8 weeks
Study: 6833654
Drug: Diltiazem 180
Normalized name: diltiazem 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 180 mg/day
Study: 9988942
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem (120 mg twice a day)
Study: 2082209
Drug: Oxiracetam treatment
Normalized name: oxiracetam
DrugBank: Oxiracetam (DB13601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam treatment
Study: 28224745
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen at a flow rate of 2 l/min
Study: 3134446
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dimethicone and senna extract
Study: 18809631
Drug: Alogliptin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (both doses)
Study: 15713945
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib for at least 3 days followed by oral valdecoxib through day 10
Study: 15713945
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo followed by oral valdecoxib
Study: 12660054
Drug: Clindamycin 300
Normalized name: clindamycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300 mg orally twice daily for 5 days
Study: 29558323
Drug: Chicory leaf
Normalized name: CHICORY LEAF
DrugBank: Chicory leaf (DB14376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicory leaf methanolic extract capsule (1 gram, twice daily for 8 weeks)
Study: 29558323
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (1 gram wheat flour, twice daily for 8 weeks)
Study: 26166797
Drug: Aflibercept therapy
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept therapy
Study: 15125551
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections
Study: 9877014
Drug: Lorazepam (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1.2 mg PO)
Study: 9877014
Drug: Scopolamine (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.3, 0.6 mg SC)
Study: 9877014
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg PO)
Study: 27933574
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of 400 mg of magnesium
Study: 22907079
Drug: Nonfat milk
Normalized name: Nonfat milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfat milk (500 ml daily for 2 weeks)
Study: 22907079
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk (500 ml daily for 2 weeks)
Study: 12768736
Drug: HBO combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO combined with medical treatment (treatment group)
Study: 6366151
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ESR and systemic symptoms
Study: 25327394
Drug: Oligofructose (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (8 g/d for ages 7-11 years and 15 g/d for ages 12-18 years) for 12 weeks
Study: 16817786
Drug: Half-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose of nafamostat mesilate (NM)